Authors
Jonas Kuon, Miriam Blasi, FFarastuk Bozorgmehr, Konrad Kokowski, Martin Faehling, Philipp Schütt, Daniel Christoph Christoph, Martin Kimmich, Eva Lotte Buchmeier, Anke Reinacher-Schick, Matthias Ulmer, Christian Meyer Zum Büschenfelde, Nicolas Moosmann, Frank Griesinger, Wolfang Schütte, Ludwig Fischer von Weikersthal, Bernd Schmidt, Wolfgang Gleiber, Heinz Kirchen, Martin Wermke, Paul La Rosé, Gerlinde Schmidtke-Schrezenmeier, Jean-Charles Moulin, Michael Boesche, Christian Grohé, Helga Bernhard, Dominik Modest, Christoph Maintz, Marc Alexander Schneider, Rouven Behnisch, Albrecht Stenzinger, Petros Christopoulos, Michael Thomas
Published in
Clinical lung cancer. Volume 27. Issue 10. Pages 1-11. Oct 09, 2026. Epub Oct 09, 2026.
Abstract
Older and vulnerable patients with metastatic non-small-cell lung cancer (NSCLC) are underrepresented in clinical trials, and evidence guiding treatment intensity remains limited. We investigated whether a modified Cancer and Aging Research Group (mCARG) score could prospectively guide chemotherapy intensity according to estimated toxicity risk.
In this randomized, open-label phase II study, 201 patients with metastatic NSCLC aged ≥ 70 years and/or Charlson Comorbidity Index (CCI) > 1 and/or ECOG performance status ≥ 2 were stratified by mCARG score. Patients with mCARG ≤ 3 received platinum-doublet chemotherapy (CTX), whereas those with mCARG > 3 received single-agent CTX. Within each stratum, patients were randomized to 4 cycles of CTX or 2 cycles followed by durvalumab. The primary endpoint was grade 3/4 treatment-related adverse events (TRAEs).
Median age was 76 years; 30% had ECOG performance status ≥ 2 and 57% had CCI > 1. After 36.8 months median follow-up, grade 3/4 TRAEs did not differ between treatment strategies (P = .81). Patients with mCARG ≤ 3 had longer PFS (6.1 vs. 3.2 months; HR 0.54) and OS (10.2 vs. 5.3 months; HR 0.48) than patients with mCARG > 3, without increased severe toxicity. Among responders, early transition to durvalumab was associated with longer duration of response and numerically longer OS (25.3 vs. 11.3 months; P = .057).
Prospective mCARG-based treatment allocation was feasible. Lower mCARG scores were associated with favorable outcomes without increased severe toxicity, although these differences should primarily be interpreted as prognostic. Early transition to durvalumab was associated with prolonged response duration and numerically longer OS among responders, supporting further evaluation of this strategy in older and vulnerable patients.
PMID:
42966192
Bibliographic data and abstract were imported from PubMed on 01 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0